ALA 2.70% 19.0¢ arovella therapeutics limited

Mid-May Artimist marketing approval, page-3

  1. 640 Posts.
    lightbulb Created with Sketch. 172
    There is a chance the letter wasn't received 14 May; however, as Sud announced they expected to receive the letter around then and that was a week ago, and given their consistent behaviour to say nothing following these foreshadowings of potential bad outcomes, it is only reasonable to expect Sud to provide an update to sh/market on whether they are still waiting or a summary of the letter (that would be bad news imho due to the previous behaviour to doctor what is presented) or best - share the letter.

    Sud now apparently have class and skill on the team, now, finally, so I would expect they now also, finally will realise the devasting effect of not speaking to and engaging the market. Yes, I know they are busy, but this is a big ticket item.

    The fact Sud have downplayed and moved the coconut shells to say Arty is a side-issue, with respect, I strongly disagree. Product aside, it represents Sud's core business (taking a medicine and making it work with oromucosal delivery for a better outcome all round/ except price perhaps - the market don't care it was the old tech or the new tech, because Sud didn't educate the market about that); it was the first technical package with an apparently solid technical team; Arty was supposed to be rock solid; and most importantly, the TGA work with companies to ensure they get ample opportunity to respond, adjust, fix in response to TGA queries and concerns. Then the exit of MS before the outcome of the TGA and around the time they were receiving feedback on their package?? It does look like one of the important things for Sud was to shed itself of all things Arty before they had their skirts lifted.

    Sud need to prove they understand and embrace credibility. I'm expecting that the old exec have now been educated about accountability to the market and the consequences for not stepping up and that there is finally oversight that makes the exec accountable and measured. I'm hoping I'm wrong that it was the mono-therapy thing that they knew was not likely to get through - heck, even HC knew that was on the cards if not addressed and SC said it was all addressed.

    Is that the sound of crickets.....? omg I hope I'm wrong - c'mon Sud, prove me wrong, p-l-e-a-s-e
    Last edited by Doole: 24/05/19
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
(20min delay)
Last
19.0¢
Change
0.005(2.70%)
Mkt cap ! $200.6M
Open High Low Value Volume
18.8¢ 19.0¢ 18.5¢ $115.0K 609.6K

Buyers (Bids)

No. Vol. Price($)
6 226209 18.5¢
 

Sellers (Offers)

Price($) Vol. No.
19.0¢ 791369 7
View Market Depth
Last trade - 15.59pm 08/11/2024 (20 minute delay) ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.